DNA Q4 2023 Earnings — Ginkgo Bioworks Holdings, Inc. Revenue & Financial Results | Market Cap Arena

DNAGinkgo Bioworks Holdings, Inc.

$418M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$35M-64.6% YoY

Gross Profit

$28M81.0% margin

Operating Income

-$178M-512.5% margin

Net Income

-$212M-609.1% margin

EPS (Diluted)

$-4.31

QoQ Revenue Growth

-37.3%

Cash Flow

Operating Cash Flow

-$58M

Free Cash Flow

-$61M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$1.7B

Total Liabilities

$568M

Stockholders' Equity

$1.1B

Cash & Equivalents

$944M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$35M	$98M	-64.6%
Gross Profit	$28M	$68M	-58.7%
Operating Income	-$178M	-$235M	+24.0%
Net Income	-$212M	-$177M	-19.9%

Revenue Segments

Service

$20M75%

Product

$6M25%